Alzheimer's disease; taking the edge off with cannabinoids?

British Journal of Pharmacology

Volumn 152, Issue 5, 2007, Pages 655-662

  Campbell, V A ^a   Gowran, A ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

amyloid; Alzheimer's disease; Cannabinoid; CB 1 receptor; CB 2 receptor; Neurodegeneration

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; ANANDAMIDE; CANNABINOID; CANNABINOID 2 RECEPTOR; DEXANABINOL; DONEPEZIL; DRONABINOL; ENDOCANNABINOID; GALANTAMINE; MEMANTINE; NOLADIN; RIMONABANT; RIVASTIGMINE; TACRINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; EXCITOTOXICITY; HUMAN; INFLAMMATION; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CANNABINOIDS; CHOLINESTERASE INHIBITORS; HUMANS; MODELS, BIOLOGICAL; PHOSPHORYLATION; TAU PROTEINS; TETRAHYDROCANNABINOL;

EID: 35648944275     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707446     Document Type: Review

References (87)

1. 1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neuroscience Lett 309: 197-201.
2. Alger BE (2006). Not too excited? Thank your endocannabinoids. Neuron 51: 393-395.
3. Alvarez A, Alarcon A, Opazo C, Campos EO, Munoz F, Calderon FH et al. (1998). Stable complexes involving acetylcholinesterase and amyloid-β-fibrils change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J Neurosci 18: 407-416.
4. Arispe N, Pollard HB, Rojas E (1993). Giant multilevel cation channels formed by Alzheimer's disease Aβ1-40 in bilayer membranes. Proc Natl Acad Sci USA 90: 10573-10577.
5. Ashton JC, Friberg D, Darlington CL, Smith PF (2006). Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci Lett 396: 113-116.
6. Bayer TA, Buslei R, Havas L, Falkai P (1999). Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci Lett 271: 126-128.
7. 2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 23: 11136-11141.
8. 2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci 27: 2396-2402.
9. Boland B, Campbell V (2003). Amyloid-induced apoptosis of cultured cortical neurones involves calpain-mediated cleavage of poly-ADP ribose polymerase. Neurobiol Aging 24: 179-186.
10. Castellano C, Rossi-Arnaud C, Cestari V, Costanzi M (2003). Cannabinoids and memory: animal studies. Curr Drug Targets CNS Neurol Disord 2: 389-402.
11. Cosman KM, Boyle LL, Porsteinsso AP (2007). Memantine in the treatment of mild-to-moderate Alzheimer's disease. Expert Opin Pharmacother 8: 203-214.
12. Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M (2007). The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol 556: 75-83.
13. Di Marzo V, Fontana A, Cadas H, Schinell S, Clmlno G, Schwartz J et al. (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurones. Nature 372: 686-691.
14. 2 receptor activation. Mol Cell Neurosci 34: 551-561.
15. Dong H, Goico B, Martin M, Csernansky CA, Bertchume A, Csernansky JG (2004). Modulation of hippocampal cell proliferation, memory and amyloid plaque deposition in APPsw (Tg2576) mutant mice by isolation stress. Neuroscience 127: 601-609.
16. 2 suppresses microglial activation. J Neuroinflamm 12: 22-29.
17. Eshhar N, Streim S, Biegon A (1993). HU-211, a non-psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture. Neuroreport 5: 237-240.
18. Esposito G, De Filippis D, Carnuccio R, Izzo AG, Iuvone T (2006b). The marijuana component, cannabidiol, inhibits β-amyloid-induced tau protein hyperphosphorylation through Wnt/β-catenin pathway rescue in PC12 cells. J Mol Med 84: 253-258.
19. Esposito G, De Filippis D, Maiuri MC, De Stefano D, Carnuccio R, Iuvone T (2006a). Cannabidiol inhibits inducible NOS expression and NO production in β-amyloid-stimulated PC12 neurons through p38 MAP kinase and NFκB involvement. Neurosci Lett 399: 91-95.
20. Eubanks LM, Rogers CJ, Beuscher AE, Koob GF, Olson AJ, Dickerson TJ et al. (2006). A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol Pharm 3: 773-777.
21. Facchinetti F, Del Giudice E, Furegato S, Passarotto M, Leon A (2003). Cannabinoids ablate release of TNFα in rat microglial cells stimulated with lipopolysaccharide. Glia 41: 161-168.
22. 2 receptor: a new target for controlling neural cell survival? Trends Pharm Sci 28: 39-45.
23. Galve-Roperh I, Aguada T, Palazuelos J, Guzman M (2007). The endocannabinoid system and neurogenesis in health and disease. Neuroscientist 13: 109-114.
24. Garcia-Arencibia M, Gonzalez S, deLago E, Ramos JA, Mechoulam R, Fernandez-Ruiz J (2007). Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 1134: 162-170.
25. Gifford AN, Bruneus M, Gatley SJ, Volkow ND (2000). Cannabinoid receptor-mediated inhibition of acetylcholine release from hippocampal and cortical synaptosomes. Br J Pharmacol 131: 645-650.
26. Grote HE, Hannan AJ (2007). Regulators of adult neurogenesis in the healthy and diseased brain. Clin Exp Pharm Phys 34: 533-545.
27. 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95: 8268-8273.
28. Hansen HH, Ikonomidou C, Bittigau P, Hansen SH, Hansen HS (2001). Accumulation of the anandamide precursor and other N-acylethanolamine phospholipids in infant rat models of in vivo necrotic and apoptotic neuronal death. J Neurochem 76: 39-46.
29. Heneka MT, O'Banion MK (2007). Inflammatory processes in Alzheimer's disease. J Neuroimmunol 184: 69-91.
30. Herbert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003). Alzheimer's disease in the US population: prevalence estimates using the 2000 census. Archiv Neurol 60: 1119-1122.
31. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11: 563-583.
32. Inestrosa NC, Alvarez A, Pecez CA, Moreno RD, Vicente M, Linker C et al. (1996). Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 16: 881-891.
33. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA (2004). Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on β-amyloid-induced toxicity in PC12 cells. J Neurochem 89: 134-141.
34. Jackson SJ, Diemel LT, Pryce G, Baker D (2005). Cannabinoids and neuroprotection in CNS inflammatory disease. J Neurol Sci 233: 21-25.
35. Jiang W, Zhang Y, Xiao L, Van Cleemput J, Ji S, Bai G (2005). Cannabinoids promote embryonic and adult hippocampal neurogenesis and produce anxiolytic and anti-depressant-like effects. J Clin Invest 115: 3104-3116.
36. Jin K, Peel AL, Mao XL, Xie L, Cottrell B, Henshall DC et al. (2004). Increased hippocampal neurogenesis in Alzheimer's disease. Proc Natl Acad Sci USA 101: 343-347.
37. Khaspekov LG, Brenz Verca MS, Frumkina LE, Hermann H, Marsicano G, Lutz B (2004). Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity. Eur J Neurosci 19: 1691-1698.
38. Kim SH, Won SJ, Mao A, Ledent C, Jin K, Greenberg DA (2006). Role for neuronal nitric-oxide synthase in cannabinoid-induced neurogenesis. J Pharmacol Exp Ther 319: 150-154.
39. LaFerla FM (2002). Calcium dyshomeostasis and intracellular signaling in Alzheimer's disease. Nat Rev Neurosci 3: 862-872.
40. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J (2005). Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 19: 96-107.
41. Lee J, Duan W, Long JM, Ingram GK, Mattson MP (2000). Dietary restriction increases the number of newly generated neural cells and induced BDNF expression in the dentate gyrus of rats. J Mol Neurosci 15: 99-108.
42. Mackie K, Hille B (1992). Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cell lines. Proc Natl Acad Sci USA 89: 3825-3829.
43. (1-40) in rat cortical synaptosomes and cultured cortical neurones: modulation by the proinflammatory cytokine interleukin-1β. J Biol Chem 275: 4713-4718.
44. 1 receptors and on-demand defense against excitotoxicity. Science 302: 84-88.
45. 1 receptor blockade. Eur J Pharmacol 477: 219-225.
46. Mi K, Johnson GV (2006). The role of tau phosphorylation in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 3: 449-463.
47. Milton NGN (2002). Anandamide and noladin ether prevent excitotoxicity of the human amyloid-β-peptide. Neurosci Lett 332: 127-130.
48. Molina-Holgado F, Pinteaux E, Moore JD, Molina-Holgado E, Guaza C, Gibson RM et al. (2003). Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci 12: 6470-6474.
49. 6-tetrahydrocannabinol 1,1-dimethylheptyl (HU-211) attenuates N-methyl-D-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain. Neurosci Lett 162: 43-45.
50. 2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse 53: 208-213.
51. Ogomori K, Kitamoto T, Tateishi J, Sato Y, Suetsugu M, Abe M (1989). Protein amyloid is widely distributed in the central nervous system of patients with Alzheimer's disease. Am J Pathol 134: 243-251.
52. 2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J 20: 2405-2407.
53. 1 cannabinoid receptors are involved in neuroprotection via NFkB. Blood Flow Metab 25: 477-484.
54. Pazos MR, Nunez E, Benito C, Tolon RM, Romero J (2004). Role of the endocannabinoid system in Alzheimer's disease: new perspectives. Life Sci 75: 1907-1915.
55. Perez J (2006). Combined cannabinoid therapy via oromucosal spray. Drugs Today 42: 495-503.
56. Pertwee RG (2005). Pharmacological actions of cannabinoids. Handb Exp Pharmacol 168: 1-51.
57. Phiel CJ, Wilson CA, Lee VM, Klein PS (2003). GSK3 regulates production of Alzheimer's disease β-amyloid peptides. Nature 423: 435-439.
58. Piomelli D (2003). The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4: 873-884.
59. Pitt D, Werner P, Raine CS (2000). Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 6: 67-70.
60. 2, cannabinoid receptors. Br J Pharmacol 150: 519-525.
61. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Caballos ML (2005). Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 25: 1904-1913.
62. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J (1995). Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45: 51-55.
63. Riedel G, Davies SN (2005). Cannabinoid function in learning, memory and plasticity. Handb Exp Pharmacol 168: 445-477.
64. Rose CR, Konnerth A (2001). Stores not just for storage, intracellular calcium release and synaptic plasticity. Neuron 31: 519-522.
65. Sanchez AJ, Gonzalez-Perez P, Galve-Roperh I, Garcia-Merino A (2006). R-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor. Biochem Pharmacol 72: 1697-1706.
66. 2 cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal 15: 851-859.
67. Shen M, Thayer SA (1998). Cannabinoid receptor agonists protect cultured mouse hippocampal neurons from excitotoxicity. Brain Res 783: 77-84.
68. Smith IF, Green KN, LaFerla FM (2005). Calcium dysregulation in Alzheimer's disease: recent advances gained from genetically modified animals. Cell Calcium 38: 427-437.
69. Smith T, Groom A, Zhu B, Turski L (2000). Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 6: 62-66.
70. Sonkusare SK, Kaul CL, Ramarao P (2005). Dementia of Alzheimer's disease and other neurodegenerative disorders - memantine, a new hope. Pharmacol Res 51: 1-17.
71. Stella N, Schweitzer P, Piomelli D (1997). A second endogenous cannabinoid that modulates long-term potentiation. Nature 388: 773-778.
72. 1 cannabinoid receptor mediates glutamatergic synaptic suppression in the hippocampus. Neuroscience 139: 795-802.
73. Twitchell W, Brown S, Mackie K (1997). Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol 78: 43-50.
74. Van Der Stelt M, Mazzola C, Espositp G, Mathias I, Petrosino S, De Filippis D et al. (2006). Endocannabinoids and β-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci 63: 1410-1424.
75. 2 receptors. Science 310: 329-332.
76. Vereker E, Campbell V, Roche E, McEntee E, Lynch MA (2000). Lipopolysaccharide inhibits long-term potentiation in the rat dentate gyrus by activation of caspase-1. J Biol Chem 275: 26252-26258.
77. Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ (1997). Effects of Dronabinol on anorexia and disturbed behaviour in patients with Alzheimer's disease. Int J Geriatr Psych 12: 913-919.
78. Walsh DM, Selkoe DJ (2007). Aβ oligomers - a decade of discovery. J Neurochem 101: 1172-1184.
79. 9- Tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology 185: 524-528.
80. Wang SJ (2003). Cannabinoid CB1 receptor-mediated inhibition of glutamate release from rat hippocampal synaptosomes. Eur J Pharmacol 469: 47-55.
81. Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M (1994). Cannabinoid receptor binding and mRNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry of normal aged and Alzheimer's brains. Neuroscience 63: 637-652.
82. Wilkinson BL, Landreth GE (2006). The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. J Neuroinflamm 3: 30-42.
83. Williams EJ, Walsh FS, Doherty P (2003). The FGF receptor uses the endocannabinoid signalling system to couple to an axonal growth response. J Cell Biol 160: 448-481.
84. 1 receptor antagonist, improves memory in a delayed radial maze task. Eur J Pharmacol 477: 213-217.
85. Wyss-Coray T (2006). Inflammation in Alzheimer's disease: driving force, bystander or beneficial response? Nat Med 12: 1005-1015.
86. Zhuang S-Y, Bridges D, Grigoenko E, McCloud S, Boon A, Hampson RE et al. (2005). Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores. Neuropharmacology 28: 1086-1096.
87. Ziemssen T (2005). Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis. J Neurol 252: 38-45.